To improve control of hypertension in patients who are already taking an ACE inhibitor or an angiotensin receptor blocker, the 2019 NICE guidelines recommend adding either a calcium channel blocker (such as amlodipine) or a thiazide-like diuretic (such as indapamide). This is a change from previous guidelines, which only recommended adding a calcium channel blocker in this situation.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Traumatic breast fat necrosis may develop following a minor or unnoticed injury in women with a high body mass index, although it is crucial to investigate any lump to exclude breast cancer. Nipple discharge is a common symptom of mammary duct ectasia, while a tender lymph node in the axilla is likely to be palpable. Paget’s disease is characterized by an eczema-like appearance of the nipple, not a lump. Fibroadenoma, also known as a breast mouse, is not attached.

Understanding Fat Necrosis of the Breast

Fat necrosis of the breast is a condition that affects up to 40% of cases and is often caused by trauma. This condition can be mistaken for breast cancer due to its physical features, such as a mass that may initially increase in size. It is important to understand that fat necrosis is not cancerous and can be treated with proper care.

Nerve Injuries and Clinical Features: A Guide

The human body is a complex system of nerves and muscles, and injuries to these structures can have a significant impact on daily life. Here is a guide to some common nerve injuries and their associated clinical features.

Common Peroneal Nerve at the Head of the Fibula
The common peroneal nerve is often damaged as it wraps around the fibular head. This can result in foot drop, weak dorsiflexion and eversion of the foot, weak extension of the toes, sensory loss over the dorsum of the foot and lateral side of the leg, and intact reflexes.

Common Peroneal Nerve at the Ankle
The common peroneal nerve bifurcates into two terminal branches shortly after passing over the fibular head. Damage to one of these branches can occur at the ankle, but not to the common peroneal nerve itself. Symptoms may include sensory loss and weakness in the affected area.

Sciatic Nerve at the Sciatic Notch
Injury to the sciatic nerve at this level can result in pain down the thigh, loss of sensation to the whole leg below the knee (except for a narrow area on the medial leg and medial foot border), widespread motor deficit, and foot drop. The ankle jerk is lost.

Tibial Nerve at the Popliteal Fossa
Damage to the tibial nerve at this level can lead to gastrocnemius paralysis, weakened inversion and plantar flexion at the ankle, and loss of the ankle jerk. This type of injury is relatively uncommon.

Tibial Nerve at the Ankle
Compression of the tibial nerve at the level of the medial malleolus can result in tarsal tunnel syndrome. Symptoms may include paraesthesiae or numbness affecting the medial ankle and plantar aspect of the foot, weakness to the toe abductors and flexors, and tenderness at the medial malleolus. Foot drop is not a feature.

In summary, nerve injuries can have a range of clinical features depending on the location and severity of the damage. It is important to seek medical attention if you suspect you have sustained a nerve injury.

Understanding Trimethoprim: Uses, Synergy, and Potential Side Effects

Trimethoprim is an antimicrobial drug that is commonly used to treat urinary tract infections and prevent Pneumocystis jirovecii pneumonia. It works by inhibiting the reduction of dihydrofolic acid to tetrahydrofolic acid, which is essential for bacterial DNA synthesis. While it is often combined with sulfamethoxazole for synergistic reasons, serum level monitoring is not required for dosage guidance. However, caution should be exercised in individuals with a predisposition to folate deficiency, as trimethoprim can lower folic acid levels and lead to megaloblastic anemia. While hepatic toxicity has not been reported, it is important to be aware of potential side effects when using this medication.

Eye Conditions in Immunocompromised Patients

Cytomegalovirus (CMV) retinitis, acute glaucoma, age-related macular degeneration, molluscum contagiosum of eyelids, and uveitis are all potential eye conditions that can affect immunocompromised patients.

CMV retinitis is a common cause of eye disease in patients with HIV, causing necrotising retinitis with visual loss. Fundoscopy demonstrates a characteristic ‘pizza pie’ picture, with flame-shaped haemorrhages and retinal infarction. Treatment involves local and/or systemic delivery of antiviral agents such as ganciclovir, valganciclovir, or foscarnet.

Acute glaucoma is a medical emergency that presents with sudden onset of severe unilateral eye pain, vomiting, red-eye, and seeing lights distorted by haloes and decreasing vision. It is not associated with HIV/low CD4+ counts.

Age-related macular degeneration is a chronic and progressive condition affecting older people, resulting in a gradual loss of vision, particularly of the central vision. It is not related to HIV and typically presents as a chronic condition.

Molluscum contagiosum of eyelids is a viral skin infection that is more common in immunocompromised hosts. However, it tends to occur on the trunk, extremities, or abdomen, and involvement of the eyelid and buccal mucosa is uncommon.

Uveitis presents with eye pain, photophobia, blurring vision with loss of peripheral vision in some patients, redness in the eye, and possibly floaters in the vision. It is associated with HLA-B27, autoimmune conditions such as Crohn’s disease, and infections such as toxoplasmosis, tuberculosis, and Lyme disease. It is not associated with HIV, and pain and photophobia are normally very prominent symptoms.

Differential Diagnosis for a Patient with Cough and Fever: Bronchopneumonia vs. Other Conditions

Bronchopneumonia is a common condition that presents with a cough and fever, along with other symptoms such as sputum production, dyspnea, and pleuritic pain. Examination findings may include decreased breath sounds and focal chest signs. A chest radiograph can confirm the diagnosis. In primary care, a CRB-65 score is used to assess mortality risk and determine where to treat the patient: one point each for acute confusion, respiratory rate (RR) ≥30/min, systolic blood pressure (BP) <90 mmHg or diastolic BP <60 mmHg, age >65 years).
CRB-65 score Mortality risk (%) – Where to treat
0 <1 At home
1-2 1-10 Hospital advised, particularly score of 2
3-4 >10 Hospital advised, may require stay in intensive therapy unit (ITU).

Other conditions that may present with similar symptoms include pneumothorax, pulmonary embolism, malignant mesothelioma, and tuberculosis. However, these conditions have distinct features that differentiate them from bronchopneumonia. For example, pneumothorax involves partial or full collapse of a lung, while pulmonary embolism results from obstruction of one or more of the pulmonary arteries. Malignant mesothelioma is a cancer that affects the pleura and peritoneum, and tuberculosis usually presents with a persistent productive cough, weight loss, night sweats, fevers, lymphadenopathy, and general malaise.

It is important to consider these differentials when evaluating a patient with cough and fever, and to use appropriate diagnostic tools to confirm the diagnosis and determine the best course of treatment.

Enalapril is an ACE inhibitor drug that inhibits the conversion of angiotensin I to angiotensin II. However, it is contraindicated in patients with bilateral renal artery stenosis as it can cause a significant increase in creatinine levels due to the constriction of the efferent arteriole by angiotensin II. Although ACE inhibitors can sometimes be used to treat hypertension caused by renal artery stenosis, close monitoring is necessary to prevent severe renal impairment. Amlodipine, a calcium channel blocker, is a suitable alternative for this patient as it has no contraindications for renovascular disease. Bendroflumethiazide, a thiazide diuretic, increases sodium excretion and urine volume by interfering with transfer across cell membranes, reducing blood volume. Indapamide, a thiazide-like diuretic, can also be used in this patient, although it is not typically the first-line treatment.

Angiotensin-converting enzyme (ACE) inhibitors are commonly used as the first-line treatment for hypertension and heart failure in younger patients. However, they may not be as effective in treating hypertensive Afro-Caribbean patients. These inhibitors are also used to treat diabetic nephropathy and for secondary prevention of ischaemic heart disease. The mechanism of action of ACE inhibitors is to inhibit the conversion of angiotensin I to angiotensin II. They are metabolized in the liver through phase 1 metabolism.

ACE inhibitors may cause side effects such as cough, which occurs in around 15% of patients and may occur up to a year after starting treatment. This is thought to be due to increased bradykinin levels. Angioedema may also occur up to a year after starting treatment. Hyperkalaemia and first-dose hypotension are other potential side effects, especially in patients taking diuretics. ACE inhibitors should be avoided during pregnancy and breastfeeding, and caution should be exercised in patients with renovascular disease, aortic stenosis, or hereditary or idiopathic angioedema.

Patients receiving high-dose diuretic therapy (more than 80 mg of furosemide a day) are at an increased risk of hypotension when taking ACE inhibitors. Before initiating treatment, urea and electrolytes should be checked, and after increasing the dose, a rise in creatinine and potassium may be expected. Acceptable changes include an increase in serum creatinine up to 30% from baseline and an increase in potassium up to 5.5 mmol/l. Patients with undiagnosed bilateral renal artery stenosis may experience significant renal impairment. The current NICE guidelines provide a flow chart for the management of hypertension.

While the combined oral contraceptive pill may increase the risk of breast and cervical cancer, it has been found to provide protection against ovarian and endometrial cancer. In fact, studies have shown that the pill can actually decrease the risk of ovarian cancer.

Pros and Cons of the Combined Oral Contraceptive Pill

The combined oral contraceptive pill is a highly effective method of birth control with a failure rate of less than 1 per 100 woman years. It does not interfere with sexual activity and its contraceptive effects are reversible upon stopping. Additionally, it can make periods regular, lighter, and less painful, and may reduce the risk of ovarian, endometrial, and colorectal cancer. It may also protect against pelvic inflammatory disease, ovarian cysts, benign breast disease, and acne vulgaris.

However, there are also some disadvantages to the combined oral contraceptive pill. One of the main issues is that people may forget to take it, which can reduce its effectiveness. It also offers no protection against sexually transmitted infections. There is an increased risk of venous thromboembolic disease, breast and cervical cancer, stroke, and ischaemic heart disease, especially in smokers. Temporary side-effects such as headache, nausea, and breast tenderness may also be experienced.

It is important to weigh the pros and cons of the combined oral contraceptive pill before deciding if it is the right method of birth control for you. While some users report weight gain while taking the pill, a Cochrane review did not support a causal relationship. Overall, the combined oral contraceptive pill can be an effective and convenient method of birth control, but it is important to discuss any concerns or potential risks with a healthcare provider.

Immediate CT scan is necessary to evaluate for raised intracranial pressure and tentorial herniation in a patient with a sluggishly responsive unilaterally dilated pupil. This is the most pressing concern, given the patient’s reduced GCS. Although other investigations will be necessary, the CT brain is the most critical test, as the patient may require urgent neurosurgical intervention to save their life.

Patients with head injuries should be managed according to ATLS principles and extracranial injuries should be managed alongside cranial trauma. There are different types of traumatic brain injuries, including extradural hematoma, subdural hematoma, and subarachnoid hemorrhage. Primary brain injury may be focal or diffuse, and secondary brain injury can occur due to cerebral edema, ischemia, infection, or herniation. Management may include IV mannitol/frusemide, decompressive craniotomy, and ICP monitoring. Pupillary findings can provide information on the location and severity of the injury.

Anatomy of the Eye: Understanding the Different Parts and Their Disorders

The eye is a complex organ that allows us to see the world around us. It is made up of several parts, each with its own function. Understanding the anatomy of the eye and the disorders that can affect it is important for maintaining good eye health.

Lens: The lens is a transparent structure located behind the pupil and iris. It helps to focus light onto the retina. Cataracts occur when the lens becomes cloudy or opaque, causing vision problems.

Cornea: The cornea is the clear dome-shaped surface of the eye that sits over the iris. It plays a role in refracting light. Damage to the cornea can cause pain and light sensitivity.

Iris: The iris is the colored part of the eye. It can be affected by disorders such as uveitis, which causes inflammation of the uvea (iris, ciliary body, and choroid).

Retina: The retina is located at the back of the eye and contains rods and cones that process incoming light. Disorders of the retina include retinitis pigmentosa, diabetic retinopathy, and retinal detachment.

Sclera: The sclera is the white part of the eye. Disorders of the sclera include scleritis, which causes redness, pain, and reduced visual acuity. It can be associated with rheumatoid arthritis.

Understanding the different parts of the eye and their functions can help you identify potential problems and seek treatment early. Regular eye exams are important for maintaining good eye health and preventing vision loss.

Medications for Type 2 Diabetes

Metformin: The Initial Drug Treatment of Choice
For adults with type 2 diabetes, standard-release metformin is the recommended initial drug treatment. The dose should be gradually increased to avoid gastrointestinal side effects. If significant GI side effects occur, modified-release metformin can be tried. Metformin reduces hepatic gluconeogenesis and increases insulin sensitivity, leading to an increase in peripheral glucose uptake. However, caution should be exercised when using metformin in patients with renal failure, and it should be stopped if the estimated glomerular filtration rate is less than 30 ml/min per 1.73m2.

Tolbutamide and Chlorpropamide: First-Generation Sulfonylureas
Tolbutamide and chlorpropamide are first-generation sulfonylureas that are no longer routinely used in the treatment of type 2 diabetes due to a higher incidence of side effects compared to newer, second-generation sulfonylureas. Chlorpropamide is not available in the UK.

Insulin: Considered for Dual Therapy
Insulin-based treatment should be considered in type 2 diabetes patients who have not achieved optimal glycated haemoglobin control with dual therapy using metformin and another oral drug. Metformin should continue to be offered to patients without contraindications or intolerance.

Pioglitazone: An Alternative Second-Line Agent
Pioglitazone can be considered as an alternative second-line agent for patients with type 2 diabetes who cannot take metformin or have not tolerated it well. It can also be used in dual therapy for first intensification of treatment.

Medical Conditions Explained: Nephrogenic Diabetes Insipidus, Cranial Diabetes Insipidus, Chronic Reflux Nephropathy, Syndrome of Inappropriate Antidiuretic Hormone Secretion, and Psychogenic Polydipsia

Nephrogenic Diabetes Insipidus (DI)
Nephrogenic DI is a condition where the kidneys are unable to concentrate urine due to resistance to the action of antidiuretic hormone (ADH). This can be caused by lithium toxicity, which is commonly used to treat bipolar affective disorder. Symptoms include passing large volumes of dilute urine and a urinary specific gravity of 1.005 or less. Treatment involves replacing fluid losses with dextrose and water or hypo-osmolar intravenous fluids, as well as a low-protein, low-sodium diet. Alternative medication to lithium may be considered after consultation with a psychiatrist.

Cranial Diabetes Insipidus
Cranial DI, also known as central or neurogenic DI, is caused by decreased secretion of ADH, resulting in polyuria and polydipsia. Urine osmolality will be less than 300 mOsm/kg after a water deprivation test, and will rise to over 750 mOsm/kg after ADH administration.

Chronic Reflux Nephropathy
Reflux nephropathy is a condition where urine flows back from the bladder to the kidneys, causing renal damage. It is typically seen in children with urinary tract abnormalities, but can also occur with conditions that obstruct urine flow. Symptoms include those of nephrotic syndrome and urinary tract infections, but this diagnosis is not consistent with the clinical presentation in this scenario.

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
SIADH is characterized by hyponatremia and hypo-osmolality due to excessive secretion or action of ADH, resulting in impaired water excretion. However, the patient in this scenario is presenting with hypernatremia, which is not consistent with SIADH.

Psychogenic Polydipsia
Psychogenic polydipsia is excessive fluid intake without physiological stimuli, often caused by psychiatric disorders such as schizophrenia or bipolar affective disorder. It is accompanied by the sensation of dry mouth.

For primary prevention of cardiovascular disease, individuals with type 1 diabetes who do not have established risk factors should be prescribed atorvastatin 20mg if they are over 40 years old, have had diabetes for more than 10 years, have established nephropathy, or have other risk factors such as obesity and hypertension. As this patient has had type 1 diabetes for over 10 years, they should be offered statins.

Statins are drugs that inhibit the action of an enzyme called HMG-CoA reductase, which is responsible for producing cholesterol in the liver. However, they can cause some adverse effects such as myopathy, which includes muscle pain, weakness, and damage, and liver impairment. Myopathy is more common in lipophilic statins than in hydrophilic ones. Statins may also increase the risk of intracerebral hemorrhage in patients who have had a stroke before. Therefore, they should be avoided in these patients. Statins should not be taken during pregnancy and should be stopped if the patient is taking macrolides.

Statins are recommended for people with established cardiovascular disease, those with a 10-year cardiovascular risk of 10% or more, and patients with type 2 diabetes mellitus. Patients with type 1 diabetes mellitus who were diagnosed more than 10 years ago, are over 40 years old, or have established nephropathy should also take statins. It is recommended to take statins at night as this is when cholesterol synthesis takes place. Atorvastatin 20mg is recommended for primary prevention, and the dose should be increased if non-HDL has not reduced for 40% or more. Atorvastatin 80 mg is recommended for secondary prevention. The graphic shows the different types of statins available.

The copper intrauterine device is the recommended form of contraception for individuals with breast cancer. Hormonal forms of contraception are not recommended and are rated as a Category 4 risk, which is deemed unacceptable for the patient’s health.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, breast feeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

Urinary retention can be caused by Amitriptyline due to its anticholinergic activity. The patient, who has a small prostate on PR examination, is currently experiencing urinary retention. None of the other medications are known to cause this condition.

Drugs that can cause urinary retention

Urinary retention is a condition where a person is unable to empty their bladder completely. This can be caused by various factors, including certain medications. Some drugs that may lead to urinary retention include tricyclic antidepressants like amitriptyline, anticholinergics such as antipsychotics and antihistamines, opioids, NSAIDs, and disopyramide. These drugs can affect the muscles that control the bladder, making it difficult to urinate.

The patient’s symptoms suggest Brown-Séquard syndrome, which is caused by a hemisection of the spinal cord. This results in ipsilateral pyramidal weakness and loss of joint position/vibration sense, along with contralateral loss of pain/temperature sensation. The patient’s lesion is located in the left mid-thoracic cord. A lesion in the left lumbosacral plexus would only affect the left lower limb. A cervical cord lesion would affect the upper limbs. A central lesion would produce bilateral symmetrical defects, which is not the case here. A right mid-thoracic cord lesion would produce similar symptoms, but on the right side instead. Other spinal cord syndromes include complete cord transection, anterior cord syndrome, subacute combined degeneration of the cord, syringomyelia, and cauda equina syndrome. Each of these has a distinct set of symptoms and affected areas.

A poor prognosis is often linked to a gradual onset rather than an acute one.

Schizophrenia is a mental disorder that can have varying prognoses depending on certain factors. Some indicators associated with a poor prognosis include a strong family history of the disorder, a gradual onset of symptoms, a low IQ, a prodromal phase of social withdrawal, and a lack of an obvious precipitant. These factors can contribute to a more severe and chronic course of the illness, making it more difficult to manage and treat. It is important for individuals with schizophrenia and their loved ones to be aware of these indicators and seek appropriate treatment and support.

The classic presentation of IgA nephropathy is visible haematuria that occurs after a recent upper respiratory tract infection. This patient’s new-onset haematuria following a recent URTI is consistent with a diagnosis of IgA nephropathy, which is the most common cause of haematuria worldwide. IgA nephropathy typically presents acutely in young males, in contrast to post-streptococcal glomerulonephritis, which presents after 2 weeks from an upper or lower respiratory tract infection. Focal segmental glomerulosclerosis and minimal change disease are unlikely diagnoses as they present with proteinuria rather than haematuria. While post-streptococcal glomerulonephritis is a possible differential diagnosis, it differs from this patient’s presentation as it typically presents with haematuria after 2 weeks following an acute infection.

Understanding IgA Nephropathy

IgA nephropathy, also known as Berger’s disease, is the most common cause of glomerulonephritis worldwide. It is characterized by the deposition of IgA immune complexes in the mesangium, leading to mesangial hypercellularity and positive immunofluorescence for IgA and C3. The classic presentation is recurrent episodes of macroscopic hematuria in young males following an upper respiratory tract infection. Unlike post-streptococcal glomerulonephritis, IgA nephropathy is not associated with low complement levels and typically does not present with nephrotic range proteinuria or renal failure.

Management of IgA nephropathy depends on the severity of proteinuria and renal function. Isolated hematuria with no or minimal proteinuria and normal GFR requires only follow-up to monitor renal function. Persistent proteinuria with normal or slightly reduced GFR can be treated with ACE inhibitors. If there is active disease or failure to respond to ACE inhibitors, immunosuppression with corticosteroids may be necessary. The prognosis of IgA nephropathy varies, with 25% of patients developing ESRF. Factors associated with a poor prognosis include male gender, proteinuria, hypertension, smoking, hyperlipidemia, and ACE genotype DD, while frank hematuria is a marker of good prognosis.

According to the 2016 guidelines of the British Thoracic Society, children should be given a specific dose of steroids based on their age. For children under 2 years, the dose should be 10 mg of prednisolone, for those aged 2-5 years, it should be 20 mg, and for those over 5 years, it should be 30-40 mg. Children who are already taking maintenance steroid tablets should receive a maximum dose of 60 mg or 2 mg/kg of prednisolone. If a child vomits after taking the medication, the dose should be repeated, and if they are unable to retain the medication orally, intravenous steroids should be considered. The duration of treatment should be tailored to the number of days required for recovery, and a course of steroids exceeding 14 days does not require tapering.

Managing Acute Asthma Attacks in Children

When it comes to managing acute asthma attacks in children, it is important to assess the severity of the attack and take appropriate action. For children between the ages of 2 and 5, those with severe or life-threatening asthma should be immediately transferred to the hospital. For moderate attacks, children should have a SpO2 level above 92% and no clinical features of severe asthma. However, for severe attacks, children may have a SpO2 level below 92%, be too breathless to talk or feed, have a heart rate above 140/min, and use accessory neck muscles. For life-threatening attacks, children may have a SpO2 level below 92%, a silent chest, poor respiratory effort, agitation, altered consciousness, and cyanosis.

For children over the age of 5, it is recommended to attempt to measure PEF in all cases. For moderate attacks, children should have a SpO2 level above 92%, a PEF level above 50% best or predicted, and no clinical features of severe asthma. For severe attacks, children may have a SpO2 level below 92%, a PEF level between 33-50% best or predicted, and be unable to complete sentences in one breath or too breathless to talk or feed. For life-threatening attacks, children may have a SpO2 level below 92%, a PEF level below 33% best or predicted, a silent chest, poor respiratory effort, altered consciousness, and cyanosis.

For children with mild to moderate acute asthma, bronchodilator therapy should be given via a beta-2 agonist and spacer (or close-fitting mask for children under 3 years old). One puff should be given every 30-60 seconds up to a maximum of 10 puffs. If symptoms are not controlled, the beta-2 agonist should be repeated and the child should be referred to the hospital. Steroid therapy should also be given to all children with an asthma exacerbation for 3-5 days, with the usual prednisolone dose varying based on age and weight.

If a child under the age of 5 has asthma that is not being controlled by a short-acting beta agonist (SABA) and a low dose of inhaled corticosteroids (ICS), then a leukotriene receptor antagonist should be added to their asthma management plan.

Managing Asthma in Children: NICE Guidelines

Asthma management in children has been updated by NICE in 2017, following the 2016 BTS guidelines. The new guidelines for children aged 5-16 are similar to those for adults, with a stepwise approach for treatment. For newly-diagnosed asthma, short-acting beta agonist (SABA) is recommended. If symptoms persist, a combination of SABA and paediatric low-dose inhaled corticosteroid (ICS) is used. Leukotriene receptor antagonist (LTRA) is added if symptoms still persist, followed by long-acting beta agonist (LABA) if necessary. Maintenance and reliever therapy (MART) is used as a combination of ICS and LABA for daily maintenance therapy and symptom relief. For children under 5 years old, clinical judgement plays a greater role in diagnosis. The stepwise approach is similar to that for older children, with an 8-week trial of paediatric moderate-dose ICS before adding LTRA. If symptoms persist, referral to a paediatric asthma specialist is recommended.

It should be noted that NICE does not recommend changing treatment for well-controlled asthma patients simply to adhere to the latest guidelines. The definitions of low, moderate, and high-dose ICS have also changed, with different definitions for adults and children. For children, <= 200 micrograms budesonide or equivalent is considered a paediatric low dose, 200-400 micrograms is a moderate dose, and > 400 micrograms is a high dose. Overall, the new NICE guidelines provide a clear and concise approach to managing asthma in children.